Their clinical significance cannot be underestimated, and as research deepens and applications expand, SGLT-2 inhibitors are poised to play an increasingly critical and widespread role in the treatment of CKD and related diseases, advancing modern nephrology and benefiting more patients. Here, SLC5A2 is linked to chronic kidney disease.